Logo

Bayer's Vitrakvi (larotrectinib) Receives Health Canada Approval for Advanced Solid Tumors Harboring NTRK Gene Fusion

Share this

Bayer's Vitrakvi (larotrectinib) Receives Health Canada Approval for Advanced Solid Tumors Harboring NTRK Gene Fusion

Shots:

  • Vitrakvi has received approval under Health Canada's NOC/c policy based on the clinical study evaluating Vitrakvi in adults and children with solid tumors harboring NTRK fusion
  •  The clinical study resulted in 75% ORR with 22% CR- 90% ORR is observed in children and 69% in adults. Vitrakvi therapy should be initiated following confirmation of NTRK gene fusion in a tumor specimen using a validated test
  • Vitrakvi is an oral selective TRK inhibitor act by shrinking the tumor or slowing/stopping its growth and has received FDA’s accelerated approval for solid tumors with NTRK gene fusion on Nov 26- 2018

Click here to­ read full press release/ article | Ref: Canada Newswire | Image: Financial Times


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions